Research: Data Problems
The race to capture generative optimism in the biotech industry
High expectations have been placed on bringing AI advances into the life sciences sector. It seems like a recent memory since blockbuster computational drug discovery IPOs like Recursion came to market, using AI to find new drugs. Things have changed a lot since then, with many companies drawing down 80-90%. In this research, we take a closer look at the next wave of enthusiasm for generative AI in biology, how the market is shaping up, and the path forward for all the capital that has flowed into this space.
You can read our research in the PDF attached. As always, we welcome any thoughts or feedback on our research.
